List view / Grid view
Subject to regulatory approval, EU member states will be supplied…
Subject to regulatory approval, EU member states will be supplied with the potentially highly effective BNT162b2 COVID-19 vaccine candidate.
The COVID-19 vaccine candidate BNT162b2, made by Pfizer and BioNTech,…
The COVID-19 vaccine candidate BNT162b2, made by Pfizer and BioNTech, has demonstrated over 90 percent efficacy in its first interim analysis during its Phase III trial.
An agreement between the US government and Pfizer and BioNTech…
An agreement between the US government and Pfizer and BioNTech will have the companies produce an initial 100 million doses of their COVID-19 vaccine candidate, with the potential for 500 million more.
